KING, WYETH TO COLLABORATE ON ALTACE

A A

King Pharmaceuticals and Wyeth Pharmaceuticals have entered into an amended co-promotion agreement regarding King's product Altace (ramipril), an angiotensin converting enzyme (ACE) inhibitor. These will be effective by Jan. 1, 2007, when King will assume full responsibility for the selling and marketing of Altace.

"Through this successful collaboration, Altace, King's flagship cardiovascular product, has grown into the leading branded ACE inhibitor, with net sales increasing from $122 million in 1999 to $554 million in 2005," said Brian A. Markison, King's president and CEO.